Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-04-21
|
BAL101553 |
treatment refractory tumors |
preclinical |
Basilea Pharmaceutica (Switzerland) |
Cancer - Oncology |
2016-04-21
|
AFM21, AFM22 (NK- and T-cell TandAbs generated against EGFRvIII) and AFM24 (EGFR/CD16A) |
solid tumors |
preclinical |
Affimed (Germany) |
Cancer - Oncology |
2016-04-21
|
MM-310 |
|
preclinical |
Merrimack Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2016-04-21
|
bimagrumab (BYM338) |
sporadic inclusion body myositis (sIBM) |
2-3 |
Novartis (Switzerland) |
Inflammatory diseases - Rare diseases |
2016-04-21
|
BMN 250 - chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulinlike growth factor 2 |
mucopolysaccharidosis type IIIB (Sanfilippo B syndrome) |
1-2 |
Biomarin Pharmaceutical (USA - CA) |
Rare diseases - Genetic diseases |
2016-04-21
|
OPT-302 |
wet age related macular degeneration (AMD) |
1-2a |
Opthea (Australia) |
Ophtalmological diseases |
2016-04-21
|
AFM13 in combination with Keytruda® (pembrolizumab) |
treatment of Hodgkin lymphoma patients relapsed or refractory to chemotherapy |
1b |
Affimed (Germany) |
Cancer - Oncology |
2016-04-21
|
BAL3833 (CCT3833) |
|
preclinical |
Basilea Pharmaceutica (Switzerland) |
Cancer - Oncology |
2016-04-21
|
MD1003 (high doses of pharmaceutical-grade biotin) |
chronic visual loss resulting from optic neuritis in multiple sclerosis |
3 |
Medday (France) |
Autoimmune diseases - Neurodegenerative diseases |
2016-04-21
|
AFM13 with checkpoint modulators, including checkpoint inhibitor PD-1 |
|
preclinical |
Affimed (Germany) |
Cancer - Oncology |
2016-04-20
|
ZVex™ platform |
|
preclinical |
Immune Design (USA - MA) |
Cancer - Oncology |
2016-04-20
|
Spinraza™ -nusinersen - ISIS-SMNRx (antisense oligonucleotide targeted to the SMN2 gene) |
spinal muscular atrophy |
2,3 |
Isis Pharmaceuticals (USA - CA), now Ionis Pharmaceuticals (USA - CA) |
Neuromuscular diseases - Rare diseases - Genetic diseases |
2016-04-20
|
G100 and ZVex™ platform |
non-Hodgkin lymphoma |
preclinical |
Immune Design (USA - MA) |
Cancer - Oncology |
2016-04-20
|
venetoclax (RG7601, GDC-0199/ABT-199) |
relapsed/refractory multiple myeloma |
3 |
Abbvie (USA - IL) Genentech, a member of Roche Group (USA - CA - Switzerland) |
Cancer - Oncology |
2016-04-20
|
JCAR016 |
WT-1-expressing non-small cell lung cancer (NSCLC), mesothelioma |
1 |
Juno Therapeutics (USA - WA) Fred Hutchinson Cancer Research Center (USA - WA) |
Cancer - Oncology |
2016-04-20
|
JCAR018 |
Follicular Lymphoma, ALL, NHL, Large Cell Lymphoma |
1 |
National Cancer Institute (NCI) Juno Therapeutics (USA - WA) |
Cancer - Oncology |
2016-04-20
|
AB-SA01 (phage cocktail targeting Staphylococcus aureus) |
Staphylococcus aureus infections in patients with chronic rhinosinusitis |
1 |
AmpliPhi BioSciences (USA - VA) |
Infectious diseases |
2016-04-20
|
ALN-TTR02 (patisiran) |
transthyretin-mediated amyloidosis (ATTR), familial amyloidotic polyneuropathy (FAP) |
2 |
Alnylam Therapeutics (USA - MA) |
Rare diseases - Genetic diseases |
2016-04-20
|
ES425 |
triple-negative breast cancer (TNBC) |
preclinical |
Emergent BioSolutions (USA - MD) Aptevo Therapeutics (USA - MD) |
Cancer - Oncology |
2016-04-20
|
CUDC-907 - mesylate synthetic small molecule inhibitor of HDAC and PI3K |
|
preclinical |
Curis (USA - MA) |
Cancer - Oncology |